Published in Eur Neuropsychopharmacol on January 20, 2011
Treatment Response in First-episode Schizophrenia. Clin Psychopharmacol Neurosci (2012) 0.95
Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci (2014) 0.80
Are lay people good at recognising the symptoms of schizophrenia? PLoS One (2013) 0.78
Prominent clinical dimension, duration of illness and treatment response in schizophrenia: a naturalistic study. Psychiatry Investig (2012) 0.77
Neurosarcoidosis and the complexity in its differential diagnoses: a review. Innov Clin Neurosci (2012) 0.77
Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone? Ther Adv Psychopharmacol (2015) 0.75
Longitudinal changes in prospective memory and their clinical correlates at 1-year follow-up in first-episode schizophrenia. PLoS One (2017) 0.75
Influencing Factors and Predictors of Early Response in Schizophrenia Patients Receiving the Paliperidone Extended-Release Tablets (Paliperidone ER). Psychiatry Investig (2013) 0.75
Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People's Republic of China. Neuropsychiatr Dis Treat (2014) 0.75
Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. Eur Child Adolesc Psychiatry (2015) 0.75
Large recurrent microdeletions associated with schizophrenia. Nature (2008) 20.25
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet (2008) 10.52
Common variants conferring risk of schizophrenia. Nature (2009) 10.37
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet (2008) 6.24
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet (2008) 4.78
WPA guidance on how to combat stigmatization of psychiatry and psychiatrists. World Psychiatry (2010) 4.26
The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry (2013) 4.16
Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry (2010) 3.88
Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet (2009) 3.86
Identifying depression in primary care: a comparison of different methods in a prospective cohort study. BMJ (2003) 3.78
Genome-wide association study of alcohol dependence. Arch Gen Psychiatry (2009) 3.08
Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol (2010) 2.74
The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int (2013) 2.73
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry (2008) 2.64
Deep brain stimulation for psychiatric disorders. Dtsch Arztebl Int (2010) 2.60
Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull (2008) 2.59
Unilateral deep brain stimulation of the nucleus accumbens in patients with treatment-resistant obsessive-compulsive disorder: Outcomes after one year. Clin Neurol Neurosurg (2009) 2.57
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
microRNA-34c is a novel target to treat dementias. EMBO J (2011) 2.44
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry (2007) 2.40
cn.MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate. Nucleic Acids Res (2012) 2.36
Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacol Res (2010) 2.26
Neuroleptic malignant syndrome or catatonia? Trying to solve the catatonic dilemma. Psychopharmacology (Berl) (2014) 2.24
Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch Gen Psychiatry (2009) 2.17
Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry (2002) 2.15
Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry (2009) 2.09
Real-time fMRI of temporolimbic regions detects amygdala activation during single-trial self-induced sadness. Neuroimage (2003) 2.09
The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorders. J Chem Neuroanat (2003) 2.08
Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry (2007) 2.05
Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. Neuroimage (2007) 2.03
Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland. J Urol (2009) 2.03
Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain (2005) 2.03
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry (2005) 1.98
Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic illness. Am J Psychiatry (2011) 1.94
Integration of fMRI and simultaneous EEG: towards a comprehensive understanding of localization and time-course of brain activity in target detection. Neuroimage (2004) 1.84
Prefrontal transcranial direct current stimulation changes connectivity of resting-state networks during fMRI. J Neurosci (2011) 1.81
Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol (2005) 1.75
Genomewide association analysis followed by a replication study implicates a novel candidate gene for neuroticism. Arch Gen Psychiatry (2008) 1.75
Factor structure and external validity of the PANSS revisited. Schizophr Res (2005) 1.74
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry (2009) 1.71
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry (2012) 1.69
FABIA: factor analysis for bicluster acquisition. Bioinformatics (2010) 1.68
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry (2003) 1.66
Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry (2009) 1.64
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry (2002) 1.63
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol (2008) 1.62
Depression-related variation in brain morphology over 3 years: effects of stress? Arch Gen Psychiatry (2008) 1.61
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry (2010) 1.61
Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci (2004) 1.58
A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry (2006) 1.57
Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry (2009) 1.56
Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD). Kidney Int (2005) 1.55
Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. Biol Psychiatry (2003) 1.55
Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology (2004) 1.55
Neuregulin 1 ICE-single nucleotide polymorphism in first episode schizophrenia correlates with cerebral activation in fronto-temporal areas. Eur Arch Psychiatry Clin Neurosci (2008) 1.55
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry (2012) 1.55
Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. J Psychiatry Neurosci (2008) 1.53
Deficient inhibitory cortical networks in antipsychotic-naive subjects at risk of developing first-episode psychosis and first-episode schizophrenia patients: a cross-sectional study. Biol Psychiatry (2012) 1.53
Multivariate network analysis of fiber tract integrity in Alzheimer's disease. Neuroimage (2006) 1.52
Response and remission criteria in major depression--a validation of current practice. J Psychiatr Res (2010) 1.52
Twenty-year graft survival and graft function analysis by a matched pair study between pediatric en bloc kidney and deceased adult donors grafts. Transplantation (2009) 1.52
Syndromes and phenomenological subtypes underlying acute mania: a factor analytic study of 576 manic patients. Am J Psychiatry (2002) 1.51
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol (2008) 1.51
Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. Int J Neuropsychopharmacol (2005) 1.50
Intervention in at-risk states for developing psychosis. Eur Arch Psychiatry Clin Neurosci (2010) 1.50
Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract (2012) 1.49
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry (2013) 1.48
Remediation of impairments in facial affect recognition in schizophrenia: efficacy and specificity of a new training program. Schizophr Res (2005) 1.48
Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J Clin Psychiatry (2004) 1.48
Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J Clin Psychiatry (2004) 1.46
Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. Arch Gen Psychiatry (2010) 1.46
Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J Biol Psychiatry (2010) 1.45
Protective drugs in acute large-dose exposure to organophosphates: a comparison of metoclopramide and tiapride with pralidoxime in rats. Anesth Analg (2005) 1.45
Targeting vascular endothelial growth factor pathway offers new possibilities to counteract microvascular disturbances during ischemia/reperfusion of the pancreas. Transplantation (2006) 1.45
Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. Brain (2004) 1.45
Gender differences in the cognitive control of emotion: An fMRI study. Neuropsychologia (2007) 1.44
Progression of corpus callosum atrophy in Alzheimer disease. Arch Neurol (2002) 1.44
Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull (2008) 1.44
Catatonia in DSM-5. Schizophr Res (2013) 1.43
Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia. J Clin Psychopharmacol (2003) 1.43
Stimulus pulse-frequency-dependent efficacy and cognitive adverse effects of ultrabrief-pulse electroconvulsive therapy in patients with major depression. J ECT (2011) 1.42
Do tetracyclines and erythromycin exert anti-acne effects by inhibition of P450-mediated degradation of retinoic acid? Exp Dermatol (2014) 1.41
Suicidality as rare adverse event of antidepressant medication: report from the AMSP multicenter drug safety surveillance project. J Clin Psychiatry (2010) 1.41
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol (2002) 1.41
Multidimensional assessment of empathic abilities: neural correlates and gender differences. Psychoneuroendocrinology (2010) 1.41